James P. Ellison

Are The Kids All Right? FDA Warning Letters Put FDA In A Bind

While FDA Suffers Staffing Cuts, Nondelegation Case In SCOTUS Is Latest Legal Challenge To Curb Agency Powers

Governmentally Recognized As Safe

FOIA Requires Transparency Of Instructions To FDA Staff, Even When Those Instructions Are To Pause Communications With The Public

What We're Watching For In The Senate Confirmation Hearings To Consider Robert F. Kennedy, Jr. To Be Secretary Of HHS

Even In "Unprecedented" Times, There Is Precedent

FDA's Proposal To Remove Oral Phenylephrine From The OTC Monograph Isn't A Surprise But What Is Left "Over-the-Counter"?

As Jurisprudence Under Loper Bright Develops, Early Scorecard Is Mixed

Keeping Your Company's Federal Contracting Options Safe In The Face Of Pending BIOSECURE Act Legislation

Regulatory Due Diligence Becomes More Critical In A "Hot" Year For Deals In The FDA Space

Fool Me Once, Shame On You. Fool Me Twice And It's A Federal Felony—Always?